Lbp Am Sa Increases Stake in Boston Scientific Corporation $BSX

Lbp Am Sa increased its stake in Boston Scientific Corporation (NYSE:BSX) by 8.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 434,393 shares of the medical equipment provider’s stock after purchasing an additional 33,534 shares during the quarter. Lbp Am Sa’s holdings in Boston Scientific were worth $41,419,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Parnassus Investments LLC lifted its position in shares of Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after acquiring an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP raised its stake in Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the period. Jennison Associates LLC raised its stake in Boston Scientific by 133.5% during the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares during the period. Marshall Wace LLP lifted its holdings in Boston Scientific by 30.7% in the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after purchasing an additional 2,301,383 shares in the last quarter. Finally, Credit Agricole S A bought a new position in Boston Scientific in the 3rd quarter worth approximately $204,812,000. Institutional investors own 89.07% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support remains: Truist trimmed its price target to $90 but kept a Buy rating, and Citi has reiterated a Buy stance (prior target reductions noted). The sustained Buy ratings support upside sentiment despite lower targets. Truist price target note Citi reiteration
• Positive Sentiment: Earnings expectations are constructive: recent pieces (Zacks, Yahoo) highlight that BSX appears positioned for an earnings beat in the upcoming report, citing favorable revenue/expense dynamics and consensus-beating potential—this can support near-term upside if results meet or beat expectations. Zacks earnings preview Yahoo earnings preview
• Neutral Sentiment: Competitive landscape update: AIP’s announced $1.27B take-private of Avanos (a competitor in some product areas) could change competitive dynamics in adjacent markets, but direct impact on BSX revenue/margins is unclear at this stage. MedTechDive Avanos takeover
• Neutral Sentiment: Market commentary: Overnight/early coverage noted BSX outperformed the broader market in recent sessions, reflecting mixed investor responses to the above factors. Zacks market note
• Negative Sentiment: Legal risk rising: Multiple law firms have filed or announced investor alerts about securities-class-action claims alleging that BSX (and some officers) misrepresented U.S. electrophysiology procedure growth; several firms are soliciting lead-plaintiff motions with a May 4, 2026 deadline. This cluster of lawsuits increases litigation risk and could pressure the stock if damages or disclosures follow. Rosen class action notice Levi & Korsinsky alert

Analyst Ratings Changes

A number of brokerages recently weighed in on BSX. Truist Financial dropped their target price on shares of Boston Scientific from $92.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday. Sanford C. Bernstein reiterated an “outperform” rating and issued a $112.00 price target on shares of Boston Scientific in a research note on Friday, February 6th. Citigroup dropped their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Boston Scientific in a report on Monday, March 16th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $102.82.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $64.61 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a 12 month low of $60.59 and a 12 month high of $109.50. The company has a market capitalization of $96.02 billion, a price-to-earnings ratio of 33.30, a PEG ratio of 0.99 and a beta of 0.78. The firm’s 50-day moving average is $70.12 and its 200 day moving average is $87.35.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.